Vanda Pharmaceuticals INC 8-K filings

Vanda Pharmaceuticals announced a 5% increase in revenue compared to the previous quarter, alongside a net loss, and provided updates on its drug pipeline and commercialization plans.

Vanda Pharmaceuticals has confirmed receipt of a revised unsolicited acquisition proposal from Future Pak, offering $7.25 to $7.75 per share in cash plus Contingent Value Rights.

Vanda Pharmaceuticals has amended its Rights Agreement to include BlackRock and its investment funds as an 'Exempt Person', subject to certain ownership and representation conditions.

Vanda Pharmaceuticals adopts a limited duration stockholder rights plan to protect shareholder interests following an unsolicited acquisition proposal.

Vanda Pharmaceuticals' Fanapt (iloperidone) has been approved by the FDA for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Vanda Pharmaceuticals has received a Complete Response Letter from the FDA regarding its supplemental New Drug Application for HETLIOZ in the treatment of insomnia.

Vanda Pharmaceuticals has disclosed the 2023 annual bonuses, 2024 base salaries, and 2024 bonus targets for its named executive officers, along with RSU awards.

Vanda Pharmaceuticals has completed the acquisition of U.S. and Canadian rights for PONVORY from Actelion, a Johnson & Johnson company, and released pro forma financial statements reflecting the transaction.

Vanda Pharmaceuticals reported a decrease in revenue for both the fourth quarter and full year 2023, alongside the acquisition of PONVORY and progress in its clinical pipeline.

Vanda Pharmaceuticals received notification from the FDA regarding deficiencies in its supplemental New Drug Application for HETLIOZ in the treatment of insomnia, precluding labeling discussions.